Shifting the disease management paradigm from glucose: what are the pros?
Stirban
Alin
A
Diabetes Center, Heart and Diabetes Center NRW Bad Oeynhausen, Ruhr-University Bochum, Bochum, Germany.
Tschoepe
Diethelm
D
Stratmann
Bernd
B
D050197:Atherosclerosis / Q000453:epidemiology; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control; D003925:Diabetic Angiopathies / Q000453:epidemiology; D003929:Diabetic Neuropathies / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000453:epidemiology; D006442:Glycated Hemoglobin / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D009765:Obesity / Q000453:epidemiology / Q000517:prevention & control; D010976:Platelet Count; D015995:Prevalence; D012307:Risk Factors
D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D008055:Lipids